Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases.

Strong and growing portfolio

We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care.

Our Immunology portfolio, with three strongly growing products that each meet high unmet medical needs, represents a new focus that builds on our heritage in rare diseases. We continue to explore further external growth opportunities to strengthen our business and late-stage pipeline, so that we can continue giving more people living with rare diseases access to innovative treatments.

Integrated biopharmaceutical company

Sobi is a biopharmaceutical company with in-house capabilities that stretch from late-stage R&D, biologics manufacturing and supply, to patient access and distribution.

Growing international presence

With our head office in Stockholm, Sweden, the Sobi organisation spans more than 30 countries, delivering treatments to patients in over 70 countries across the globe. We see geographic expansion as an important aspect of our strategy, and are pursuing it through acquisitions, greater market penetration and by establishing operations in new markets.

e-mail: info.greece@sobi.com

The post SOBI SINGLE MEMBER IKE appeared first on Hellenic-Swedish Chamber of Commerce.